External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setback</li><li>Perceptive Advisors increased stake in anticipation of reproxalap approval for dry eye disease</li><li>Potential option agreement with AbbVie could greatly benefit ALDX financially, making its share price undervalued</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setbackPerceptive Advisors increased stake in anticipation of reproxalap approval for dry eye diseasePotential option agreement with AbbVie could greatly benefit ALDX financially, making its share price undervaluedThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Aldeyra Therapeutics Inc (ALDX) - Wednesday, Apr 10, 2024

United States

Aldeyra Therapeutics, Inc. provides medical services. The Company deals in treatment and research for dry eye disease, allergic conjunctivitis, and other forms of ocular inflammation. Aldeyra Therapeutics serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aldeyra Therapeutics (ALDX US)

Aldeyra Therapeutics Inc (ALDX) - Wednesday, Apr 10, 2024

Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setback. Perceptive Advisors increased stake in anticipation...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)